Areas Under Investigation in Ph-Like ALL
Sarah K. Tasian, MD, discusses what she finds most interesting about Philadelphia chromosome (Ph-like) acute lymphoblastic leukemia.
Sarah K. Tasian, MD, attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses what she finds most interesting about Philadelphia chromosome (Ph-like) acute lymphoblastic leukemia (ALL).
Tasian is surprised by how heterogenous the disease is and how they are always discovering new fusions. Despite the number of lesions, she says patients have either 1 of 2 pathways:BCR-ABLor CRLF2-R/JAK.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
January 22nd 2025The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in an investigator-initiated trial in China.
Read More
